4:51 PM
 | 
Jul 19, 2013
 |  BC Extra  |  Company News

FDA, EMA to review Biogen Idec's Plegridy for MS

Biogen Idec Inc. (NASDAQ:BIIB) said FDA accepted for review a BLA and EMA accepted...

Read the full 53 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >